Joel Greenblatt Cassava Sciences Inc Transaction History

Gotham Asset Management, LLC

  • $9.41 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$41.79 - $135.3 $1.66 Million - $5.37 Million
-39,726 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$32.15 - $89.72 $1.28 Million - $3.56 Million
39,726 New
39,726 $3.39 Million

Others Institutions Holding SAVA

# of Institutions
207
Shares Held
14M
Call Options Held
2.98M
Put Options Held
6.57M
View Full List

About CASSAVA SCIENCES INC

SAVA Quotes by TradingView
  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $160M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email